We have recently demonstrated that the combined expression of the three solute carriers (SLC1A5, SLC7A5 and SLC3A2) is associated with poor prognosis and short BCSS, particularly in the highly proliferative BC subtypes.9 Here, SLC3A2 is linked to breast cancer.